

Zelluna Capital Markets Update 2026

Advancing a first-in-class TCR-NK cell therapy platform for solid tumours into the clinic

Date: Tuesday 14 April 2026

Time: 11:30 – 13:00 CET, Lunch served

Venue: Hotel Continental, Oslo (Meeting Room 4)

Format: Presentation, discussion and Q&A 12:00-13:00



Professor Fiona Thistlethwaite

Clinical Lead, AICT, The Christie, UK
Lead PI for Zelluna's ZIMA-101 study



Dr Namir Hassan, PhD

CEO, Zelluna ASA
Former VP, Immunocore (led early clinical development of TCR therapies)

Please confirm attendance by 7 April via ir@zelluna.com

A recording will be available on our website after the event

Kind regards,
Zelluna ASA



zelluna